Mitochon Pharmaceuticals
CompanyUnited States
Mitochon Pharmaceuticals develops 2 assets, the furthest preclinical (MP-101 in Alzheimer's disease). Mostly small molecule; based in the United States.
- 2
- Assets
- Furthest stage
- Preclinical
- Raised
- US$1.6m
- 0
- Trials
- 0
- Signals
Pipeline
2Mitochondrial uncoupler that increases energy expenditure, improves calcium handling, and reduces reactive oxygen species production.
Preclinical, Small molecule, Alzheimer's disease, amyotrophic lateral sclerosis
Slow-release prodrug of 2,4-dinitrophenol that induces mitochondrial uncoupling.
Preclinical, Small molecule, Alzheimer's disease, amyotrophic lateral sclerosis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Funding rounds and grants1
- People4
- Similar companies6